RedHill Biopharma to Participate in Upcoming BTIG and Intellisight Conferences

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will participate in the following virtual conferences in August:

BTIG Virtual Biotechnology Conference:
Fireside chat discussion and Q&A
Date: Tuesday, August 11, 2020
Time: 9:00 a.m. EDT
Speaker: Dror Ben-Asher, Chief Executive Officer

Intellisight 2020 9^th Annual Investment Conference:
Company presentation and Q&A
Date: Wednesday, August 12, 2020
Time: 9:15 a.m. EDT
Speaker: Guy Goldberg, Chief Business Officer

The fireside chat and presentation will be broadcasted live and available via replay for 30 days on the Company’s website: https://ir.redhillbio.com

About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs, Movantik^® for opioid-induced constipation in adults¹, Talicia^® for the treatment of Helicobacter pylori (H. pylori) infection in adults² and Aemcolo^® for the treatment of travelers’ diarrhea in adults³. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva^®), a first–in–class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and ongoing Phase 2 studies for prostate cancer and cholangiocarcinoma; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (iv) RHB-102 (Bekinda^®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB–106, an encapsulated bowel preparation, and (vi) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19. More information about the Company is available at www.redhillbio.com.